AU2012272680A1 - Compounds and methods of prophylaxis and treatment regarding nicotinic receptor antagonists - Google Patents

Compounds and methods of prophylaxis and treatment regarding nicotinic receptor antagonists Download PDF

Info

Publication number
AU2012272680A1
AU2012272680A1 AU2012272680A AU2012272680A AU2012272680A1 AU 2012272680 A1 AU2012272680 A1 AU 2012272680A1 AU 2012272680 A AU2012272680 A AU 2012272680A AU 2012272680 A AU2012272680 A AU 2012272680A AU 2012272680 A1 AU2012272680 A1 AU 2012272680A1
Authority
AU
Australia
Prior art keywords
disease
disorder
impaired
compounds
receptor antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012272680A
Other languages
English (en)
Inventor
Youyi Peng
John Tomesch
Lawrence P. Wennogle
Qiang Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of AU2012272680A1 publication Critical patent/AU2012272680A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012272680A 2011-06-24 2012-06-22 Compounds and methods of prophylaxis and treatment regarding nicotinic receptor antagonists Abandoned AU2012272680A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/US2011/041866 WO2012177263A1 (en) 2011-06-24 2011-06-24 Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists
AUPCT/US2011/041866 2011-06-24
US201161501207P 2011-06-25 2011-06-25
US61/501,207 2011-06-25
PCT/US2012/043813 WO2012178057A1 (en) 2011-06-24 2012-06-22 Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists

Publications (1)

Publication Number Publication Date
AU2012272680A1 true AU2012272680A1 (en) 2014-02-20

Family

ID=47422974

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012272680A Abandoned AU2012272680A1 (en) 2011-06-24 2012-06-22 Compounds and methods of prophylaxis and treatment regarding nicotinic receptor antagonists
AU2012272646A Ceased AU2012272646B2 (en) 2011-06-24 2012-06-22 Organic compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2012272646A Ceased AU2012272646B2 (en) 2011-06-24 2012-06-22 Organic compounds

Country Status (13)

Country Link
US (4) US9469625B2 (enExample)
EP (1) EP2723173B1 (enExample)
JP (1) JP6087911B2 (enExample)
KR (1) KR20140036305A (enExample)
CN (1) CN103717069B (enExample)
AU (2) AU2012272680A1 (enExample)
BR (1) BR112013033306A2 (enExample)
CA (2) CA2840047A1 (enExample)
ES (1) ES2627338T3 (enExample)
IL (1) IL230036A (enExample)
MX (1) MX342322B (enExample)
RU (1) RU2610094C2 (enExample)
WO (3) WO2012177263A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012177263A1 (en) * 2011-06-24 2012-12-27 Intra-Cellular Therapies, Inc. Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists
US11491150B2 (en) 2017-05-22 2022-11-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2019152680A1 (en) * 2018-01-31 2019-08-08 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating cancer using chrna6 inhibitors
WO2020146384A1 (en) 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds
WO2021008565A1 (zh) * 2019-07-16 2021-01-21 清华大学 乙酰胆碱通路调节剂在治疗癌症中的用途
EP4238970A1 (en) * 2022-03-03 2023-09-06 InterAx Biotech AG Modulators of ackr3 and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
PE20021019A1 (es) * 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
ES2338539T3 (es) * 2001-11-01 2010-05-10 Icagen, Inc. Pirazolamidas para uso en el tratamiento del dolor.
BR0315056A (pt) 2002-11-01 2005-08-16 Pharmacia & Upjohn Co Llc Compostos tendo tanto atividade agonista nicotìnica de alfa7 quanto atividade antagonista de 5ht3 para o tratamento de doenças do sistema nervoso central
MXPA05007689A (es) * 2003-01-22 2005-09-30 Pharmacia & Upjohn Co Llc Tratamiento de enfermedades con agonistas completos del receptor alfa-7 de nach.
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP2006525355A (ja) * 2003-05-01 2006-11-09 アボット・ラボラトリーズ ナトリウムチャンネルモジュレーターとしてのピラゾール−アミドおよびスルホンアミド
US20040220170A1 (en) * 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
EP1638944A1 (en) * 2003-06-12 2006-03-29 Eli Lilly And Company Tachykinin receptor antagonists
WO2009112459A1 (en) 2008-03-11 2009-09-17 Neurosearch A/S Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors
US20100179186A1 (en) 2008-10-10 2010-07-15 University Of Kentucky Research Foundation USE OF A NOVEL ALPHA-7 nAChR ANTAGONIST TO SUPPRESS PATHOGENIC SIGNAL TRANSDUCTION IN CANCER AND AIDS
WO2012177263A1 (en) 2011-06-24 2012-12-27 Intra-Cellular Therapies, Inc. Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists

Also Published As

Publication number Publication date
US20160237061A1 (en) 2016-08-18
WO2012177263A1 (en) 2012-12-27
WO2012178112A1 (en) 2012-12-27
AU2012272646A1 (en) 2014-02-20
US9708294B2 (en) 2017-07-18
MX342322B (es) 2016-09-23
MX2014000255A (es) 2014-08-21
WO2012178057A1 (en) 2012-12-27
US9469625B2 (en) 2016-10-18
IL230036A (en) 2016-10-31
US9452160B2 (en) 2016-09-27
JP6087911B2 (ja) 2017-03-01
AU2012272646B2 (en) 2016-09-08
CA2840047A1 (en) 2012-12-27
EP2723173B1 (en) 2017-04-19
US20140205596A1 (en) 2014-07-24
US20140205595A1 (en) 2014-07-24
CN103717069A (zh) 2014-04-09
KR20140036305A (ko) 2014-03-25
CN103717069B (zh) 2018-06-05
US9108949B2 (en) 2015-08-18
BR112013033306A2 (pt) 2016-08-16
RU2610094C2 (ru) 2017-02-07
JP2014517078A (ja) 2014-07-17
US20160008343A1 (en) 2016-01-14
EP2723173A1 (en) 2014-04-30
CA2840373A1 (en) 2012-12-27
ES2627338T3 (es) 2017-07-27
EP2723173A4 (en) 2015-02-18
RU2014102191A (ru) 2015-07-27

Similar Documents

Publication Publication Date Title
US9452160B2 (en) Compounds and methods of prophylaxis and treatment regarding nicotinic receptor antagonists
Cheng et al. Huperzine A, a novel promising acetylcholinesterase inhibitor
Carlsson et al. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence
Rothman et al. Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction
Alinari et al. Bruton's tyrosine kinase inhibitors in B‐cell non‐Hodgkin's lymphomas
EP2429518A1 (en) Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
Holman In defense of secondary pharmaceutical patents: A response to the UN's guidelines for pharmaceutical patent examination
Xu et al. Advances in cancer chemotherapeutic drug research in China
Sharda et al. A computer-aided drug designing for pharmacological inhibition of mutant ALK for the treatment of non-small cell lung cancer
Donvito et al. Neuronal nicotinic acetylcholine receptors mediate∆ 9‐THC dependence: Mouse and human studies
Peng et al. Discovery of novel α7 nicotinic receptor antagonists
Liang et al. Progress in the study of mefloquine as an antibiotic adjuvant for combination bacterial inhibition treatment
Yoshikawa et al. The broad‐spectrum anti‐emetic activity of AS‐8112, a novel dopamine D2, D3 and 5‐HT3 receptors antagonist
Karmakar et al. 9-Phenyl Acridine: a possible poly (ADP-ribose) polymerase-1 inhibitor
De Sarro et al. Repeated treatment with quinolones potentiates the seizures induced by aminophylline in genetically epilepsy-prone rats
Li et al. The discovery of risperidone: a case of multiple target antipsychotic drug
Toma et al. Neuronal nicotinic acetylcholine receptor agonists
O'Callaghan et al. Discovery of Novel alpha7 Nicotinic Receptor Antagonists
Furukawa et al. Antiemetic effects of a potent and selective neurokinin-1 receptor antagonist, FK886, on cisplatin-and apomorphine-induced emesis in dogs
JP2020507609A (ja) アルコール使用障害の治療
Huang et al. 12Advances in Cancer Chemotherapeutic Drug Research in China
JP2017514891A (ja) 化学的に誘発された神経障害及びその症状の予防及び／または治療のための中枢作用性アセチルコリンエステラーゼ阻害剤、ならびに対応する組成物、使用、方法、及びキット
HK40042967B (zh) 作为d-氨基酸氧化酶抑制剂的已知化合物的用途
Horton Discovery of GZ-793A, a Novel VMAT2 Inhibitor and Potential Pharmacotherapy for Methamphetamine Abuse
Jaeger Discovery of Novel Negative Allosteric Modulators of Neuronal Nicotinic Acetylcholine Receptors: Implications in the Treatment of Addiction and Other Neurological Disorders

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ COMPOUNDS AND METHODS OF PROPHYLAXIS AND TREATMENT REGARDING NICOTINIC RECEPTOR ANTAGONISTS

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application